Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Finding Europe's Head Traveler Objections: An Excursion Through Famous Attractions - 2NASA study shows how satellite 'light pollution' hinders space telescopes
- 3Multi-million-euro win in Spanish lottery in doubt due to oversight
- 4Vote In favor of Your Favored Pet Consideration Administration
- 5The 20 Most sultry Style of the Time
- Earth's newfound 'episodic-squishy lid' may guide our search for habitable worlds
- Fundamental Monetary Guidance for Going into Business
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- 7 Delightful Ferris Wheels, Do You Like Them?
- 2024 Ferrari Roma With Just One Owner & 3,300 Miles For Sale At $...
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- Knesset FADC extends emergency draft for 280,000 IDF reservists until January 1
